Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxingloushi Decoction
- Development stage
- Preclinical
- Administration
- Oral
01
Overview
Maxingloushi Decoction is a traditional Chinese medicine used to mitigate lung inflammation in conditions like chronic obstructive pulmonary disease (COPD). It works by regulating the PD-1/PD-L1 axis, reducing PD-1 expression and increasing PD-L1 expression, which helps in restoring immune balance and reducing inflammation[1][2][4].
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on Maxingloushi Decoction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maxingloushi Decoction.